ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2015.2816 ETM-0-0-2816 Articles Naringenin attenuates pressure overload-induced cardiac hypertrophy ZHANGNING 1 2 * YANGZHENG 1 2 * YUANYUAN 1 2 LIFANGFANG 1 2 LIUYUAN 1 2 MAZHENGUO 1 2 LIAOHAIHAN 1 2 BIANZHOUYAN 1 2 ZHANGYAO 1 2 ZHOUHENG 1 2 DENGWEI 1 2 ZHOUMENGQIAO 1 2 TANGQIZHU 1 2 Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China Cardiovascular Research Institute, Wuhan University, Wuhan, Hubei 430060, P.R. China Correspondence to: Professor Qizhu Tang, Department of Cardiology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, Hubei 430060, P.R. China, E-mail: qztang@whu.edu.cn

Contributed equally

 12 2015 19 10 2015 10 6 2206 2212 29092014 01092015 Copyright © 2015, Spandidos Publications 2015

Cardiac hypertrophy is characterized by abnormal enlargement of cardiomyocytes and disproportionate accumulation of extracellular interstitial fibrosis, which are major predictors of the development of coronary artery disease and heart failure. Naringenin is a bitter principle component of grapefruit that has numerous pharmacological effects, including anti-inflammatory, hypolipidemic, antithrombotic and antiatherogenic properties. In order to investigate whether naringenin is able to exert a protective effect against cardiac hypertrophy induced by pressure overload, aortic banding (AB) was performed to induce cardiac hypertrophy in mice, and naringenin was administered for 7 weeks. A total of 60 mice were allocated into four groups: Sham + vehicle, AB + vehicle, sham + naringenin and AB + naringenin. Naringenin treatment attenuated cardiac dysfunction, as indicated by the results of echocardiography and catheter-based measurements at 8 weeks post-surgery. The extent of cardiac hypertrophy was assessed by the heart weight/body weight, heart weight/tibial length and lung weight/body weight ratios, in addition to the cardiomyocyte cross-sectional area and the mRNA expression levels of hypertrophic maker, all of which were mitigated by naringenin administration. Naringenin also inhibited the expression of transforming growth factor-β1, connective tissue growth factor, collagen Iα and collagen IIIα, and attenuated interstitial fibrosis. In addition, naringenin downregulated the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathways. In conclusion, naringenin attenuated cardiac hypertrophy and interstitial fibrosis, in addition to improving left ventricular function in pressure-overloaded mice. The cardioprotective effect exerted by naringenin may be associated with the inhibition of PI3K/Akt, ERK and JNK signaling pathways.

 cardiac hypertrophy naringenin aortic banding pharmacology Introduction

Pathological cardiac hypertrophy develops in response to hemodynamic overload, which is a major predictor for the development of coronary artery disease and heart failure (1). Preventing and postponing the progression of cardiac hypertrophy may serve as an effective therapeutic strategy for the treatment of patients with heart failure (2). Clinical management of pathological cardiac hypertrophy is targeted against the underlying cause of the condition and typically involves the administration of certain pharmacological agents, such as angiotensin-converting-enzyme inhibitor and angiotensin receptor blockers (3). However, although current pharmacological approaches appear to be beneficial in improving the quality of life of patients with heart failure, they do not markedly reduce the mortality rates (4). A previous study showed that puerarin attenuates the cardiac hypertrophy induced by pressure overload by downregulating phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and c-Jun N-terminal kinase (JNK) signaling pathways (5). Therefore, a key future challenge is the identification of pharmacological agents that alleviate progressive myocardial dysfunction and unfavorable remodeling, improve the quality of life and reduce the mortality rate of patients with heart failure.

Naringenin is a bitter principle component of grapefruit (Citrus paradisi) that exhibits a variety of pharmacological effects, including anti-inflammatory (6), hypolipidemic, antithrombotic and antiatherogenic properties (5). The dietary consumption of citrus fruits is associated with a reduced rate of acute coronary events (7), and naringenin appears to exert beneficial effects on the cardiovascular system (8). Naringenin has been demonstrated to promote endothelium-independent vasorelaxing effects on rat aortic rings that have been precontracted with noradrenaline (9). Furthermore, naringenin may be able to alleviate myocardial ischemia/reperfusion injury (10). In addition, due to its radical-scavenging and iron-chelating properties, naringenin may potentially protect against doxorubicin-induced cardiac toxicity (6). However, it currently remains clear whether naringenin is able to mitigate the development of pressure overload-induced cardiac hypertrophy and postpone the progression of heart failure.

In the present study, aortic banding (AB) was used to induce cardiac hypertrophy in C57BL/6 mice in order to investigate whether naringenin is able to exert a protective effect against cardiac hypertrophy, fibrosis and left ventricular dysfunction, and to identify the possible mechanisms underlying these effects. In addition, the study aimed to determine whether naringenin is able to influence the activation of mitogen-activated protein kinase (MAPK) and PI3K/Akt signaling pathways, which are activated by pressure overload.

 Materials and methods <sec> <title>Animals and animal models

All the experimental procedures were performed in accordance with the institutional guidelines of the Animal Care and Use Committee of Renmin Hospital of Wuhan University (Wuhan, China) and in accordance with the Guide for the Care of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85–23, revised in 1996). This study was approved by the ethics committee of Wuhan University (Wuhan, China). A total of 60 male C57BL/6 mice (age, 8–10 weeks; weight, 23.5–27.5 g) were purchased from the Institute of Laboratory Animal Science, CAMS & PUMC (Beijing, China). All animals were allowed to acclimatize to the laboratory environment for 1 week, then randomly distributed to either a sham surgery or AB group, which were respectively treated without or with naringenin (normal diet containing ~100 mg/kg body weight/day naringenin) for 7 weeks, beginning 1 week after AB surgery. The dose of naringenin was administered according to the protocol described in a previous study (10). Non-naringenin (vehicle) mice received a normal diet of rodent chow. Subsequently, the C57BL/6 mice were allocated at random into four groups: Sham + naringenin, AB + naringenin, sham + vehicle and AB + vehicle (n=15 per group). AB was performed as described previously (11). At 8 weeks after surgery, the animals were euthanized by cervical dislocation while anesthetized with 1.5% isoflurane, and the hearts were dissected and weighed to calculate the heart weight/body weight (HW/BW, in mg/g), heart weight/tibia length (HW/TL, in mg/mm) and lung weight/body weight (LW/BW, in mg/g) ratios in the naringenin-treated and vehicle-treated mice. All surgeries and analyses were performed in a blinded manner.

 Echocardiography and hemodynamics

Transthoracic echocardiography and hemodynamic analysis were performed according to the protocol described in a previous study (12). The animals were subjected to echocardiographic and pressure-volume analyses at 8 weeks after surgery. For echocardiography measurements, mice was anesthetized with 1.5% isoflurane, and measurements were obtained using a MyLab™ 30CV ultrasound system (Esaote SpA, Genoa, Italy) equipped with a 10-MHz linear array ultrasound transducer. The left ventricle (LV) dimensions were assessed in a parasternal short-axis view during systole or diastole. The LV end-systolic diameter (LVESD), LV end-diastolic diameter (LVEDD) and wall thickness were obtained from the smallest or largest area of the LV. In the process of hemodynamic measurements, a microtip catheter transducer (Millar, Inc., Houston, TX, USA) was inserted into the right carotid artery and advanced into the LV of mice anesthetized with 1.5% isoflurane. The signals were continuously recorded using a Millar Pressure-Volume system (Millar, Inc.), and the maximal rate of pressure development (dP/dtmax) and minimal rate of pressure decay (dP/dtmin) were processed using PVAN data analysis software (Millar, Inc.).

 Histological analysis

The hearts of the mice were excised, arrested in diastole with 10% KCl, weighed, placed in 10% formalin and embedded in paraffin. The hearts were cut transversely close to the apex to visualize the left and right ventricles. Sections of the heart (4–5 mm) were obtained and mounted onto slides, stained with hematoxylin and eosin (H&E; Baso Diagnostics, Inc., Zhuhai, China) for histopathological analysis. For collagen deposition determination, tissue sections were stained with 0.1% picro-sirius red (PSR) red satin solution (Dechuang, Inc., Beijing, China) for 1 h at room temperature, then washed in 0.5% acetic acid for 2 min and visualized by light microscopy (ECLIPSE 80i; Nikon Corporation, Tokyo, Japan). For myocyte cross-sectional area examination, sections were stained with H&E. A single myocyte per field was observed using the Image-Pro Plus 6.0 quantitative digital image analysis system (Media Cybernetics, Inc., Rockville, MD, USA). The outline of 100–200 myocytes in the LV was analyzed for each group.

 Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis

In order to investigate the relative mRNA expression levels of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), β-myosin heavy chain (β-MHC), transforming growth factor-β (TGF-β), connective tissue growth factor (CTGF), collagen Iα and collagen IIIα, total mRNA was extracted from frozen, pulverized LV tissue using TRIzol reagent (cat. no. 15596026; Invitrogen Life Technologies, Carlsbad, CA, USA). cDNA was synthesized from 2 mg total RNA using oligo (dT) primers and an RT-for-PCR kit (cat. no. 04896866001; Roche Diagnostics GmbH, Mannheim, Germany). PCR amplifications were performed using a LightCycler 480 SYBR Green Master Mix (cat. no. 04896866001; Roche Diagnostics GmbH). The cycling conditions for PCR were as follows: 10 sec denaturation at 95°C, 20 sec annealing at 60°C and 20 sec at 72°C extension. The results were normalized against the expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

In order to determine the activation state of MAPK and PI3K/Akt signaling, cardiac tissues were lysed in RIPA lysis buffer. Subsequently, the protein concentration of all samples was measured using a bicinchoninic assay kit (cat. no. 23227; Thermo Fisher Scientific, Waltham, MA, USA). Tissue lysate samples (50 mg) were subjected to 10% SDS-PAGE, and subsequently transferred to polyvinylidene difluoride membranes (cat. no. IPFL00010; EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% non-fat milk and then incubated overnight at 4°C with the following rabbit primary antibodies against: Phosph-PI3K p85Tyr458/p55Tyr199 (4288), total-PI3K p85 (4257), phospho-AktSer473 (4060), total-Akt (4691), phospho-glycogen synthase kinase 3βSer9 (GSK3β) (9322), total-GSK3β (9315), phospho-extracellular signal-regulated kinase (ERK)1/2Thr202/Tyr204 (4370), total-ERK1/2 (4695), phospho-p38Thr180/Tyr182 (4511), total-p38 (9212), phospho-JNK1/2Thr183/Tyr18 (4668), total-JNK1/2 (9285) (1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA). In addition, rabbit anti-GAPDH antibody (1:1,000; MB001) was purchased from Bioworld Technology, Inc. (St. Louis Park, MN, USA). The blots were then scanned using a two-color infrared imaging system (Odyssey; LI-COR Biosciences, Lincoln, NE, USA). Specific protein expression levels were normalized against those of GAPDH protein for total tissue lysates.

 Statistical analysis

Data are expressed as the mean ± standard deviation. Differences among groups were determined by two-way analysis of variance followed by a post-hoc Tukey's test. Comparisons between two groups were performed using an unpaired Students t-test. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Naringenin protects against pressure overload-induced cardiac hypertrophy

To determine the role of naringenin in cardiac remodeling, hypertrophic responses were evaluated using histological analysis and RT-qPCR. H&E staining of gross heart tissue confirmed the protective effect of naringenin against cardiac hypertrophy. H&E staining of gross heart tissue indicated that the increase in the cardiomyocyte cross-sectional area following AB was inhibited by naringenin (Fig. 1A). At 8 weeks of AB treatment, mice in the AB + vehicle group exhibited significant increases in the HW/BW, HW/TL and LW/BW ratios compared with the sham + vehicle group. Administration of naringenin evidently decreased the HW/BW and HW/TL ratios following AB (P<0.05), indicating the attenuation of cardiac hypertrophy; however, no statistically significant difference was detected in the LW/BW ratio (P>0.05) (Fig. 1B). Furthermore, in mice subjected to AB, the mRNA expression levels of hypertrophic markers, including ANP, BNP and β-MHC, was mitigated by naringenin, as determined by RT-qPCR (P<0.05) (Fig. 1C).

 Naringenin improves impaired cardiac function following AB

To evaluate the effect of naringenin in the progression of cardiac dysfunction, AB or sham surgery was performed. After 8 weeks, the chamber diameter, wall thickness and function of the LV were assessed by echocardiography. No statistically significant differences were detected between the vehicle and naringenin-treated mice that underwent the sham surgery. However, following AB surgery, the naringenin-treated mice exhibited alleviated cardiac hypertrophy and cardiac dysfunction compared with the vehicle mice, which was determined by measuring the LVESD, LVEDD, fractional shortening and ejection fraction (P<0.05) (Fig. 2A and B). The dP/dtmax and dP/dtmin, analyzed by pressure-volume loop, revealed that the naringenin treatment exerted a beneficial effect on the hemodynamic function of LV (Fig. 2C).

 Naringenin alleviates the fibrotic response induced by pressure overload

To clarify the effects of naringenin on perivascular and interstitial fibrosis, cardiac interstitial collagen deposition was detected using PSR staining. The results demonstrated that the fibrotic area ratio was decreased significantly in mice that received naringenin treatment following AB surgery (P<0.05). However, there was no significant difference in the extent of cardiac fibrosis in the sham-operated mice after 8 weeks (P>0.05) (Fig. 3A and B). To further elucidate the effect of naringenin on collagen synthesis, the mRNA expression levels of TGF-β, CTGF, collagen Iα and collagen IIIα, which are known mediators of fibrosis, were analyzed. Compared with the vehicle group, decreased expression levels of TGF-β, CTGF, collagen Iα and collagen IIIα were detected in the naringenin group following the AB surgery (P<0.05) (Fig. 3C).

 Naringenin attenuates cardiac hypertrophy by inhibiting the activation of JNK, ERK and PI3K/Akt signaling pathways

To elucidate the molecular mechanisms by which naringenin mediates cardiac hypertrophy, the activation states of the MAPK and PI3K/Akt signaling pathways were evaluated. The results indicated that the upregulation of phospho-JNK and phospho-ERK was mitigated in mice that received naringenin treatment following the AB surgery (P<0.05). However, the level of phospho-p38 was unchanged (P>0.05) (Fig. 4A and B). Furthermore, the role of the PI3K/Akt signaling pathway, a key mechanism that regulates the progression of pathological cardiac hypertrophy, was investigated. Naringenin also appeared to decrease the expression of phosphorylated Akt and its downstream target phospho-GSK3β subsequent to pressure overload (P<0.05) (Fig. 4C and D).

 Discussion

Naringenin is widely used in traditional Chinese medicine due to its multiple pharmacological effects, including anti-inflammatory (5), anti-hyperlipidemic, anti-thrombotic and anti-atherosclerotic properties. Naringenin promotes endothelium-independent vasorelaxing effects on rat aortic rings pre-contracted with noradrenaline (9), and is able to alleviate the myocardial ischemia/reperfusion injury (10). A previous study reported that naringenin is able to protect against doxorubicin-induced cardiac toxicity, due to its radical-scavenging and iron-chelating properties (6). To the best of our knowledge, the present study demonstrated for the first time that naringenin is able to attenuate pressure overload-induced cardiac hypertrophy. Furthermore, the results indicated that naringenin may improve cardiac function and attenuate the interstitial fibrosis.

Cardiac hypertrophy is characterized by the abnormal enlargement of cardiomyocytes, originating from an increase in myocyte size and the proliferation of non-muscle cells (13). Numerous clinical studies have indicated that sustained cardiac hypertrophy is a maladaptive process, ultimately leading to decompensated heart failure (14). Characterization of the pathogenesis of cardiac hypertrophy may provide novel approaches for the prevention of heart failure progression. Blockage of the MAPK signaling pathway, downstream of which a variety of intracellular transcription factors are phosphorylated during the reprogramming of cardiac gene expression, prevents the progression of cardiac hypertrophy (15). In addition, the ERK pathway serves a critical function in cardiac hypertrophy, and may be activated by mitogen-activated protein kinase kinase (known as MEK or MAPKK)-dependent phosphorylation (16). JNKs are specific transducers of the stress response, and are known as stress-activated protein kinases (17). In the heart, JNK activity is upregulated following pressure overload (18). However, Lei et al (19) reported that the expression of p38 MAPK was upregulated transiently in transverse AB-induced pressure overload in mice. However, the molecular mechanism by which naringenin mitigates cardiac hypertrophy remain unclear. Therefore, in the present study the activation of potential signaling pathways, including the MAPK and PI3K/Akt pathways, was evaluated. The results of the present study demonstrate that naringenin is able to mitigate the activation of the ERK and JNK signaling pathways. PI3K/Akt is another crucial signaling pathway in the process of cardiac hypertrophy. Various studies have indicated that the engagement of the p85SH2 domains of PI3K by pTyr relieved the p85-mediated inhibition of p110 isoforms, led to the activation of class I PI3Ks (p110α, p110δ, p110β) and always resulted in Akt activation (20). The short-term activation of Akt known to be caused by physiological hypertrophy and through such pathways may be cardioprotective, despite causing mild heart enlargement; however, the long-term activation promoted pathological cardiac hypertrophy and heart failure (21). Inhibition of GSK3β, downstream of Akt, is required for compensation of pressure overload (22), and has been shown to be a negative regulator of cardiac hypertrophy (23). Notably, naringenin attenuates the activation of Akt in the progression of cardiac hypertrophy.

Fibrosis is another integral feature of cardiac hypertrophy, which is characterized by the disproportionate expression of the extracellular matrix and accumulation of fibrillar collagen. The primary collagen types in the heart are type I and III, which together account for >90% of the total collagen and are the predominant contributors to interstitial fibrosis in the progression of heart failure (24). The present results indicate that the mRNA expression levels of TGF-β1, CTGF, collagen Iα and collagen IIIα were increased following AB, and that naringenin evidently alleviated this upregulation. In addition, the results of the PSR staining suggested that naringenin attenuates the interstitial and perivascular fibrosis induced by pressure overload (25). Notably, naringenin has the pharmacological effect of normalizing the expression of pro-fibrotic genes, indicating that naringenin may be effective in attenuating extracellular remodeling following pressure overload. These effects require verification by additional studies.

In conclusion, the results of the present study demonstrated that naringenin exerts a pharmacological effect against the progression of cardiac hypertrophy induced by pressure overload. Inhibition of the JNK, ERK and PI3K/Akt signaling pathways by naringenin may serve a crucial function in the mitigation of the development of cardiac hypertrophy in structure remodeling and function alteration induced by pressure overload. This anti-fibrotic function is mediated by the downregulation of interstitial fibrosis gene expression, including that of TGF-β1, CTGF, collagen Iα and collagen IIIα, which occur in response to pressure overload. These results partially elucidate the pharmacological effects of naringenin and the pathways involved in its protective role, which may provide a novel pharmacotherapeutic strategy for the treatment of cardiac hypertrophy in pressure overload and limit the progression of heart failure.

 Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (no. 81270303 and 81300104), the Specialized Research Fund for the Doctoral Program of Higher Education of China (no. 20130141120042) and the Natural Science Foundation of Hubei Province, China (no. 2013CFB303).

 References BalakumarPJagadeeshGMultifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?Pharmacol Res62365383201010.1016/j.phrs.2010.07.00320643208 GjesdalOBluemkeDALimaJACardiac remodeling at the population level-risk factors, screening and outcomesNat Rev Cardiol8673685201110.1038/nrcardio.2011.15422027657 HellawellJLMarguliesKBMyocardial reverse remodelingCardiovasc Ther30172181201210.1111/j.1755-5922.2010.00247.x21108773 van BerloJHMailletMMolkentinJDSignaling effectors underlying pathologic growth and remodeling of the heartJ Clin Invest1233745201310.1172/JCI6283923281408 YuanYZongJZhouHBianZYDengWDaiJGanHWYangZLiHTangQZPuerarin attenuates pressure overload-induced cardiac hypertrophyJ Cardiol637381201410.1016/j.jjcc.2013.06.00823906530 MiddletonEJrKandaswamiCEffects of flavonoids on immune and inflammatory cell functionsBiochem Pharmacol4311671169199210.1016/0006-2952(92)90489-61562270 OshipuraKJHuFBMansonJEStampferMJRimmEBSpeizerFEColditzGAscherioARosnerBSpiegelmanDWillettWCThe effect of fruit and vegetable intake on risk for coronary heart diseaseAnn Intern Med13411061114200110.7326/0003-4819-134-12-200106190-0001011412050 DauchetLFerrièresJArveilerDYarnellJWGeyFDucimetièrePRuidavetsJBHaasBEvansABinghamAFrequency of fruit and vegetable consumption and coronary heart disease in France and Northern Ireland: The PRIME studyBr J Nutr92963972200410.1079/BJN2004128615613259 SaponaraSTestaiLIozziDMartinottiEMartelliAChericoniSSgaragliGFusiFCalderoneV(+/−)-Naringenin as large conductance Ca(2+)-activated K+ (BKCa) channel opener in vascular smooth muscle cellsBr J Pharmacol14910131021200610.1038/sj.bjp.070695117088866 TestaiLMartelliAMarinoAD'AntongiovanniVCiregiaFGiustiLLucacchiniAChericoniSBreschiMCCalderoneVThe activation of mitochondrial BK potassium channels contributes to the protective effects of naringenin against myocardial ischemia/reperfusion injuryBiochem Pharmacol8516341643201310.1016/j.bcp.2013.03.01823567997 YanLHuangHTangQZZhuLHWangLLiuCBianZYLiHBreviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signalingJ Cell Biochem10911581171201020127712 ZhouHBianZYZongJDengWYanLShenDFGuoHDaiJYuanYZhangRStem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overloadHypertension60802809201210.1161/HYPERTENSIONAHA.112.19889522851736 CarreñoJEApablazaFOcaranzaMPJalilJECardiac hypertrophy: Molecular and cellular eventsRev Esp Cardiol594734862006(In Spanish)10.1157/1308790016750145 FreyNOlsonENCardiac hypertrophy: The good, the bad and the uglyAnnu Rev Physiol654579200310.1146/annurev.physiol.65.092101.14224312524460 LorenzKSchmittJPVidalMLohseMJCardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signalingInt J Biochem Cell Biol4123512355200910.1016/j.biocel.2009.08.00219666137 LorenzKSchmittJPSchmitteckertEMLohseMJA new type of ERK1/2 autophosphorylation causes cardiac hypertrophyNat Med157585200910.1038/nm.189319060905 PaulAWilsonSBelhamCMRobinsonCJScottPHGouldGWPlevinRStress-activated protein kinases: Activation, regulation and functionCell Signal9403410199710.1016/S0898-6568(97)00042-99376221 SopontammarakSAliharoobAOcampoCArcillaRAGuptaMPGuptaMMitogen-activated protein kinases (p38 and c-Jun NH2-terminal kinase) are differentially regulated during cardiac volume and pressure overload hypertrophyCell Biochem Biophys436176200510.1385/CBB:43:1:06116043884 LeiBChessDJKeungWO'SheaKMLopaschukGDStanleyWCTransient activation of p38 MAP kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPKJ Mol Cell Cardiol45404410200810.1016/j.yjmcc.2008.06.00818639556 VanhaesebroeckBGuillermet-GuibertJGrauperaMBilangesBThe emerging mechanisms of isoform-specific PI3K signallingNat Rev Mol Cell Biol11329341201010.1038/nrm288220379207 ChaanineAHHajjarRJAKT signalling in the failing heartEur J Heart Fail13825829201110.1093/eurjhf/hfr08021724622 BadorffCRuettenHMuellerSStahmerMGehringDJungFIhlingCZeiherAMDimmelerSFas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overloadJ Clin Invest109373381200210.1172/JCI1377911827997 HaqSChoukrounGKangZBRanuHMatsuiTRosenzweigAMolkentinJDAlessandriniAWoodgettJHajjarRGlycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophyJ Cell Biol151117130200010.1083/jcb.151.1.11711018058 CreemersEEPintoYMMolecular mechanisms that control interstitial fibrosis in the pressure-overloaded heartCardiovasc Res89265272201110.1093/cvr/cvq30820880837 HutchinsonKRGuggilamACismowskiMJGalantowiczMLWestTAStewartJAJrZhangXLordKCLucchesiPATemporal pattern of left ventricular structural and functional remodeling following reversal of volume overload heart failureJ Appl Physio11117781788201110.1152/japplphysiol.00691.2011

Effect of naringenin on cardiac hypertrophy. (A) Gross hearts (top), whole heart section (middle; magnification, ×10) and cardiomyocyte cross-sectional area (bottom; magnification, ×400) stained with hematoxylin and eosin at 8 weeks after AB surgery. Naringenin treatment alleviated cardiac hypertrophy and decreased the cardiomyocyte cross-sectional area following AB surgery. (B) Results of the HW/BW, LW/BW and HW/TL ratios, and myocyte CSA of the indicated groups. (C) Expression of transcripts for ANP, BNP and β-MHC of the indicated groups were determined by reverse transcription-polymerase chain reaction analysis (fold changes). *P<0.05 vs. corresponding sham group. #P<0.05 vs. AB + vehicle group. AB, aortic banding; 8W, 8 weeks; ANP, atrial natriuretic peptide; β-MHC, β-myosin heavy chain; BNP, B-type natriuretic peptide; HW, heart weight; BW, body weight; TL, tibial length; CSA, cross-sectional area.

Echocardiography and pressure-volume analysis results indicating that naringenin improves the cardiac function. (A) Representative M-mode images of AB and sham groups. (B) Naringenin attenuated pressure overload-induced increased LV diameters, including the LVESD, LVEDD, FS and EF. (C) Cardiac function data of hemodynamic parameters including dp/dtmax and dp/dtmin. *P<0.05 vs. corresponding sham group. #P<0.05 vs. AB + vehicle group. AB, aortic banding; EF, ejection fraction; LVEDD, left ventricular (LV) end-diastolic diameter; LVESD, LV end-systolic diameter; FS, fractional shortening; dp/dtmax, maximal rate of pressure development; dp/dtmin, minimal rate of pressure decay

Naringenin attenuates cardiac interstitial fibrosis subsequent to pressure overload. (A) Cardiac interstitial fibrosis determined in heart sections of the indicated groups by picrosirius red staining, naringenin treatment decreased cardiac interstitial fibrosis induced by pressure-overload after AB surgery (×100). (B) Fibrotic areas ratio of histological sections were quantified by an image-analysis system. (C) mRNA expression levels of TGF-β1, CTGF, collagen Iα and collagen IIIα in the myocardium of the indicated groups, determined using reverse transcription-polymerase chain reaction analysis. *P<0.05 vs. corresponding sham group. #P<0.05 vs. AB + vehicle group. AB, aortic banding; LV, left ventricular; CTGF, connective tissue growth factor; TGF-β1, transforming growth factor-β1.

Effects of naringenin on mitogen-activated protein kinases and PI3K/AKT signalling in response to hypertrophic stimuli. (A) Representative and (B) quantitative expression of phosphorylated and total ERK1/2, JNK1/2, p38, and the effects of naringenin on indicated groups. (C) Representative and (D) quantitative blots of phosphorylated and total PI3K, Akt, GSK3β in the heart tissues of mice in the indicated groups, with GAPDH used as the loading control. *P<0.05 vs. corresponding sham group. #P<0.05 vs. AB + vehicle group. AB, aortic banding; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; GSK3β, glycogen synthase kinase 3β; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.